Literature DB >> 28295306

Osteoactivin regulates head and neck squamous cell carcinoma invasion by modulating matrix metalloproteases.

Oneida A Arosarena1,2, Eric W Barr3, Ryan Thorpe4, Hilary Yankey4, Joseph T Tarr4, Fayez F Safadi5.   

Abstract

Nearly 60% of patients with head and neck squamous cell carcinoma (HNSCC) die of metastases or locoregional recurrence. Metastasis is mediated by cancer cell migration and invasion, which are in part dependent on extracellular matrix degradation by matrix metalloproteinases. Osteoactivin (OA) overexpression plays a role in metastases in several malignancies, and has been shown to upregulate matrix metalloproteinase (MMP) expression and activity. To determine how OA modulates MMP expression and activity in HNSCC, and to investigate OA effects on cell invasion, we assessed effects of OA treatment on MMP mRNA and protein expression, as well as gelatinase and caseinolytic activity in HNSCC cell lines. We assessed the effects of OA gene silencing on MMP expression, gelatinase and caseinolytic activity, and cell invasion. OA treatment had differential effects on MMP mRNA expression. OA treatment upregulated MMP-10 expression in UMSCC14a (p = 0.0431) and SCC15 (p < 0.0001) cells, but decreased MMP-9 expression in UMSCC14a cells (p = 0.0002). OA gene silencing decreased MMP-10 expression in UMSCC12 cells (p = 0.0001), and MMP-3 (p = 0.0005) and -9 (p = 0.0036) expression in SCC25 cells. In SCC15 and SCC25 cells, OA treatment increased MMP-2 (p = 0.0408) and MMP-9 gelatinase activity (p < 0.0001), respectively. OA depletion decreased MMP-2 (p = 0.0023) and -9 (p < 0.0001) activity in SCC25 cells. OA treatment increased 70 kDa caseinolytic activity in UMSCC12 cells consistent with tissue type plasminogen activator (p = 0.0078). OA depletion decreased invasive capacity of UMSCC12 cells (p < 0.0001). OA's effects on MMP expression in HNSCC are variable, and may promote cancer cell invasion.
© 2017 Wiley Periodicals, Inc.

Entities:  

Keywords:  cell lines; extracellular matrix; human; matrix metalloproteinases; neoplasm invasion

Mesh:

Substances:

Year:  2017        PMID: 28295306      PMCID: PMC5592128          DOI: 10.1002/jcp.25900

Source DB:  PubMed          Journal:  J Cell Physiol        ISSN: 0021-9541            Impact factor:   6.384


  100 in total

1.  Use of gel zymography to examine matrix metalloproteinase (gelatinase) expression in brain tissue or in primary glial cultures.

Authors:  Harald Frankowski; Yu-Huan Gu; Ji Hoe Heo; Richard Milner; Gregory J Del Zoppo
Journal:  Methods Mol Biol       Date:  2012

2.  DC-HIL is a negative regulator of T lymphocyte activation.

Authors:  Jin-Sung Chung; Kota Sato; Irene I Dougherty; Ponciano D Cruz; Kiyoshi Ariizumi
Journal:  Blood       Date:  2007-02-06       Impact factor: 22.113

3.  Expression of MMPS, MT-MMP, and TIMPs in squamous cell carcinoma of the oral cavity: correlations with tumor invasion and metastasis.

Authors:  S Kurahara; M Shinohara; T Ikebe; S Nakamura; M Beppu; A Hiraki; H Takeuchi; K Shirasuna
Journal:  Head Neck       Date:  1999-10       Impact factor: 3.147

4.  Expression of membrane type I-matrix metalloproteinase in oral squamous cell carcinoma.

Authors:  Hoon Myoung; Myung-Jin Kim; Seong-Doo Hong; Jae-Il Lee; Chang-Yun Lim; Sam-Pyo Hong
Journal:  Cancer Lett       Date:  2002-11-28       Impact factor: 8.679

5.  Localization of matrix metalloproteinase 9 to the cell surface provides a mechanism for CD44-mediated tumor invasion.

Authors:  Q Yu; I Stamenkovic
Journal:  Genes Dev       Date:  1999-01-01       Impact factor: 11.361

6.  CR011, a fully human monoclonal antibody-auristatin E conjugate, for the treatment of melanoma.

Authors:  Kam Fai Tse; Michael Jeffers; Vincent A Pollack; Denise A McCabe; Melanie L Shadish; Nikolai V Khramtsov; Craig S Hackett; Suresh G Shenoy; Bing Kuang; Ferenc L Boldog; John R MacDougall; Luca Rastelli; John Herrmann; Michael Gallo; Gadi Gazit-Bornstein; Peter D Senter; Damon L Meyer; Henri S Lichenstein; William J LaRochelle
Journal:  Clin Cancer Res       Date:  2006-02-15       Impact factor: 12.531

7.  Overexpression of cyclin D2 is associated with increased in vivo invasiveness of human squamous carcinoma cells.

Authors:  Shao Chen Liu; Daniel E Bassi; Shi Yu Zhang; Dana Holoran; Claudio J Conti; Andres J P Klein-Szanto
Journal:  Mol Carcinog       Date:  2002-07       Impact factor: 4.784

8.  Osteoactivin, an anabolic factor that regulates osteoblast differentiation and function.

Authors:  Samir M Abdelmagid; Mary F Barbe; Mario C Rico; Sibel Salihoglu; Israel Arango-Hisijara; Abdul Hafez Selim; Michael G Anderson; Thomas A Owen; Steven N Popoff; Fayez F Safadi
Journal:  Exp Cell Res       Date:  2008-03-10       Impact factor: 3.905

9.  Tumor cell and carcinoma-associated fibroblast interaction regulates matrix metalloproteinases and their inhibitors in oral squamous cell carcinoma.

Authors:  Alexandra Fullár; Ilona Kovalszky; Mario Bitsche; Angela Romani; Volker Hans Schartinger; Georg Mathias Sprinzl; Herbert Riechelmann; József Dudás
Journal:  Exp Cell Res       Date:  2012-04-01       Impact factor: 3.905

10.  Osteoactivin (GPNMB) ectodomain protein promotes growth and invasive behavior of human lung cancer cells.

Authors:  Moses O Oyewumi; Dharani Manickavasagam; Kimberly Novak; Daniel Wehrung; Nikola Paulic; Fouad M Moussa; Gregory R Sondag; Fayez F Safadi
Journal:  Oncotarget       Date:  2016-03-22
View more
  6 in total

Review 1.  Glycoprotein nonmetastatic melanoma protein B: A key mediator and an emerging therapeutic target in autoimmune diseases.

Authors:  Pei-Suen Tsou; Amr H Sawalha
Journal:  FASEB J       Date:  2020-05-23       Impact factor: 5.191

2.  GPNMB overexpression is associated with extensive bone metastasis and poor prognosis in renal cell carcinoma.

Authors:  Jian-Po Zhai; Zhen-Hua Liu; Hai-Dong Wang; Guang-Lin Huang; Li-Bo Man
Journal:  Oncol Lett       Date:  2021-12-01       Impact factor: 2.967

3.  The suppressive effects of miR-508-5p on the odontogenic differentiation of human dental pulp stem cells by targeting glycoprotein non-metastatic melanomal protein B.

Authors:  Fengxi Liu; Xin Wang; Yun Yang; Rongrong Hu; Wenhao Wang; Yuliang Wang
Journal:  Stem Cell Res Ther       Date:  2019-01-22       Impact factor: 6.832

4.  Glycoprotein NMB promotes tumor formation and malignant progression of laryngeal squamous cell carcinoma.

Authors:  Lev Manevich; Yukari Okita; Yasuhito Okano; Takehito Sugasawa; Kunio Kawanishi; Thanasis Poullikkas; Linda T L Dang Cao; Ling Zheng; Masahiro Nakayama; Shin Matsumoto; Keiji Tabuchi; Mitsuyasu Kato
Journal:  Cancer Sci       Date:  2022-05-18       Impact factor: 6.518

5.  GPNMB-Positive Cells in Head and Neck Squamous Cell Carcinoma-Their Roles in Cancer Stemness, Therapy Resistance, and Metastasis.

Authors:  Yohei Kawasaki; Hitomi Suzuki; Shinsuke Suzuki; Takechiyo Yamada; Maya Suzuki; Ayumi Ito; Haruka Hatakeyama; Masahito Miura; Yasufumi Omori
Journal:  Pathol Oncol Res       Date:  2022-08-19       Impact factor: 2.874

6.  Functional Domains and Evolutionary History of the PMEL and GPNMB Family Proteins.

Authors:  Paul W Chrystal; Tim Footz; Elizabeth D Hodges; Justin A Jensen; Michael A Walter; W Ted Allison
Journal:  Molecules       Date:  2021-06-09       Impact factor: 4.411

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.